STOCK TITAN
  1. Home
  2. News
  3. AZN

Astrazeneca plc - AZN STOCK NEWS

Welcome to our dedicated news page for Astrazeneca plc (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on Astrazeneca plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Astrazeneca plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Astrazeneca plc's position in the market.

News
ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer
Rhea-AI Summary
ENHERTU receives approval in the EU for the treatment of advanced non-small cell lung cancer with HER2 mutation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
none
-
News
Datopotamab deruxtecan plus IMFINZI® (durvalumab) demonstrated robust and durable tumor responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA Phase Ib/II trial
Rhea-AI Summary
AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan plus IMFINZI shows a confirmed objective response rate of 79% in patients with triple-negative breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial
Rhea-AI Summary
Updated results from the BEGONIA phase 1b/2 trial showed that the combination of datopotamab deruxtecan and durvalumab demonstrated a confirmed objective response rate of 79% in patients with previously untreated advanced or metastatic triple negative breast cancer. The median progression-free survival was 13.8 months and the median duration of response was 15.5 months. The safety profile of the combination was consistent with known profiles of both agents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer
Rhea-AI Summary
Positive results from the DUO-E Phase III trial show that IMFINZI plus chemotherapy, followed by either IMFINZI monotherapy or IMFINZI plus LYNPARZA, improves progression-free survival in patients with advanced or recurrent endometrial cancer. The combination treatments reduced the risk of disease progression or death by 45% and 29% compared to chemotherapy alone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
TAGRISSO® (osimertinib) plus chemotherapy reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases at baseline
Rhea-AI Summary
AstraZeneca's TAGRISSO shows improvement in CNS progression-free survival in FLAURA2 Phase III trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
IMFINZI® (durvalumab) plus chemotherapy more than doubled pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers versus chemotherapy alone
Rhea-AI Summary
Positive results from the MATTERHORN Phase III trial showed that AstraZeneca's IMFINZI in combination with standard-of-care chemotherapy demonstrated a significant improvement in pathologic complete response for patients with gastric and gastroesophageal junction cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
none
News
Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry
Rhea-AI Summary
Meharry Medical College and partners launch Together for CHANGE initiative to increase genomic data for people of African ancestry and enhance representation in STEM careers
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.83%
Tags
none
-
News
SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care
Rhea-AI Summary
SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center, and AstraZeneca collaborate to improve global access to cancer testing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.83%
Tags
none
-
News
TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer
Rhea-AI Summary
AstraZeneca's supplemental New Drug Application (sNDA) for TAGRISSO® (osimertinib) in combination with chemotherapy has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The FDA action date for their regulatory decision is anticipated during the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none
News
Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers
Rhea-AI Summary
Fusion Pharmaceuticals presents preclinical data on FPI-2068 at cancer conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
clinical trial
Stock AZN logo
Astrazeneca plc

Nasdaq:AZN

AZN Rankings

#37 Ranked by Market Cap
#1673 Ranked by Stock Gains
#1171 Ranked by Dividends

AZN Stock Data

212.97B
1.54B
0.01%
16.8%
0.25%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United Kingdom
Cambridge

About AZN

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.